secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001790340-25-000039
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports positive Phase 2a data for IMM-1-104 in pancreatic cancer; cash runway into 2026
--------------------------------------------------------------------------------

- Phase 2a data: IMM-1-104 + mGnP showed 43% ORR, 86% DCR; + mFFX showed 50% ORR vs historic 23% and 32%.
- Planning underway for potential global pivotal trial of IMM-1-104 in first-line pancreatic cancer.
- Cash $36.1M at Dec 31, 2024; plus $13.7M from ATM in Jan 2025; runway into 2026.
- Named Dr. Igor Matushansky as Chief Medical Officer to lead clinical programs.
- Phase 1 pancreatic cancer patient on IMM-1-104 monotherapy for 13+ months with stable disease and 91% CA 19-9 reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000039/0001790340-25-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000039/imrx-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001790340-25-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer